Go Pro
NASDAQ:HCWB

HCW Biologics Q3 2025 Earnings Report

HCW Biologics logo
$5.07 -0.19 (-3.54%)
As of 01:02 PM Eastern
This is a fair market value price provided by Massive. Learn more.

HCW Biologics EPS Results

Actual EPS
-$12.12
Consensus EPS
$9.48
Beat/Miss
Missed by -$21.60
One Year Ago EPS
N/A

HCW Biologics Revenue Results

Actual Revenue
$0.00 million
Expected Revenue
$7.00 million
Beat/Miss
Missed by -$7.00 million
YoY Revenue Growth
N/A

HCW Biologics Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Friday, November 14, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

HCW Biologics' Q2 2026 earnings is estimated for Friday, August 7, 2026, based on past reporting schedules

HCW Biologics Earnings Headlines

Buy the “unseen winner of the AI race” before July 22
Marc Chaikin - the analyst who called Nvidia before a 45,000% surge - says one overlooked AI stock could split into three separate companies in a rare event called a 'starburst' before July 22. Investors who buy shares before the announcement could automatically receive equal shares in each spinoff. A similar starburst at GE unlocked $184 billion for shareholders across three new companies.tc pixel
HCWB Share News Today
See More HCW Biologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HCW Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HCW Biologics and other key companies, straight to your email.

About HCW Biologics

HCW Biologics (NASDAQ:HCWB), a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

View HCW Biologics Profile